A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00091663 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

5000

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Non-small-cell Lung Carcinoma

Interventions

DRUG: Tarceva (erlotinib HCl)

Sponsor

Genentech, Inc.